135 related articles for article (PubMed ID: 10140531)
1. Returns to R&D on new drug introductions in the 1980s.
Grabowski HG; Vernon JM
J Health Econ; 1994 Dec; 13(4):383-406. PubMed ID: 10140531
[TBL] [Abstract][Full Text] [Related]
2. The distribution of sales revenues from pharmaceutical innovation.
Grabowski HG; Vernon J
Pharmacoeconomics; 2000; 18 Suppl 1():21-32. PubMed ID: 11151306
[TBL] [Abstract][Full Text] [Related]
3. Returns on research and development for 1990s new drug introductions.
Grabowski H; Vernon J; DiMasi JA
Pharmacoeconomics; 2002; 20 Suppl 3():11-29. PubMed ID: 12457422
[TBL] [Abstract][Full Text] [Related]
4. New estimates of drug development costs.
Frank RG
J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
[No Abstract] [Full Text] [Related]
5. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
6. Estimating the cost of new drug development: is it really 802 million dollars?
Adams CP; Brantner VV
Health Aff (Millwood); 2006; 25(2):420-8. PubMed ID: 16522582
[TBL] [Abstract][Full Text] [Related]
7. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
8. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
Cockburn IM; Henderson RM
J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047
[TBL] [Abstract][Full Text] [Related]
9. What does R&D really cost?
Huff B
GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
[No Abstract] [Full Text] [Related]
10. A closer look at the returns and risk of pharmaceutical R&D.
Joglekar P; Paterson ML
J Health Econ; 1986 Jun; 5(2):153-77. PubMed ID: 10287224
[TBL] [Abstract][Full Text] [Related]
11. Notable deals in the pharmaceutical industry in the fourth quarter of 2016.
D'Souza P
Drugs Today (Barc); 2017 Jan; 53(1):75-82. PubMed ID: 28387386
[TBL] [Abstract][Full Text] [Related]
12. OTA report assails profits on new drugs.
Wagner L; Weissenstein E
Mod Healthc; 1993 Mar; 23(9):3. PubMed ID: 10124249
[No Abstract] [Full Text] [Related]
13. Cost of innovation in the pharmaceutical industry.
DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
J Health Econ; 1991 Jul; 10(2):107-42. PubMed ID: 10113009
[TBL] [Abstract][Full Text] [Related]
14. Research and development costs for drugs.
Riggs TL
Lancet; 2004 Jan; 363(9404):184. PubMed ID: 14738789
[No Abstract] [Full Text] [Related]
15. Rising research and development costs for new drugs in a cost containment environment.
DiMasi JA
Pharmacoeconomics; 1992; 1(Suppl 1):13-20. PubMed ID: 10146926
[TBL] [Abstract][Full Text] [Related]
16. Drug costs: research and development costs: the great illusion.
Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
[TBL] [Abstract][Full Text] [Related]
17. Geriatric medications in the pipeline.
Beary JF
Health Aff (Millwood); 1990; 9(3):157-60. PubMed ID: 2227774
[No Abstract] [Full Text] [Related]
18. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
Ledley FD; McCoy SS; Vaughan G; Cleary EG
JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
[TBL] [Abstract][Full Text] [Related]
19. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
Wouters OJ; McKee M; Luyten J
JAMA; 2020 Mar; 323(9):844-853. PubMed ID: 32125404
[TBL] [Abstract][Full Text] [Related]
20. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
Prasad V; Mailankody S
JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
